Literature DB >> 19899826

Quantitative phosphoproteomic analysis of the STAT3/IL-6/HIF1alpha signaling network: an initial study in GSC11 glioblastoma stem cells.

Carol L Nilsson1, Roslyn Dillon, Arugadoss Devakumar, Stone D-H Shi, Michael Greig, John C Rogers, Bryan Krastins, Michael Rosenblatt, Gregory Kilmer, Michael Major, Barbara J Kaboord, David Sarracino, Taha Rezai, Amol Prakash, Mary Lopez, Yongjie Ji, Waldemar Priebe, Frederick F Lang, Howard Colman, Charles A Conrad.   

Abstract

Initiation and maintenance of several cancers including glioblastoma (GBM) may be driven by a small subset of cells called cancer stem cells (CSCs). CSCs may provide a repository of cells in tumor cell populations that are refractory to chemotherapeutic agents developed for the treatment of tumors. STAT3 is a key transcription factor associated with regulation of multiple stem cell types. Recently, a novel autocrine loop (IL-6/STAT3/HIF1alpha) has been observed in multiple tumor types (pancreatic, prostate, lung, and colon). The objective of this study was to probe perturbations of this loop in a glioblastoma cancer stem cell line (GSC11) derived from a human tumor by use of a JAK2/STAT3 phosphorylation inhibitor (WP1193), IL-6 stimulation, and hypoxia. A quantitative phosphoproteomic approach that employed phosphoprotein enrichment, chemical tagging with isobaric tags, phosphopeptide enrichment, and tandem mass spectrometry in a high-resolution instrument was applied. A total of 3414 proteins were identified in this study. A rapid Western blotting technique (<1 h) was used to confirm alterations in key protein expression and phosphorylation levels observed in the mass spectrometric experiments. About 10% of the phosphoproteins were linked to the IL-6 pathway, and the majority of remaining proteins could be assigned to other interlinked networks. By multiple comparisons between the sample conditions, we observed expected changes and gained novel insights into the contribution of each factor to the IL6/STAT3/HIF1alpha autocrine loop and the CSC response to perturbations by hypoxia, inhibition of STAT3 phosphorylation, and IL-6 stimulation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19899826     DOI: 10.1021/pr9007927

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  42 in total

1.  Quantitative proteomic analysis revealed lovastatin-induced perturbation of cellular pathways in HL-60 cells.

Authors:  Xiaoli Dong; Yongsheng Xiao; Xinning Jiang; Yinsheng Wang
Journal:  J Proteome Res       Date:  2011-10-21       Impact factor: 4.466

2.  Sulfonium ion derivatization, isobaric stable isotope labeling and data dependent CID- and ETD-MS/MS for enhanced phosphopeptide quantitation, identification and phosphorylation site characterization.

Authors:  Yali Lu; Xiao Zhou; Paul M Stemmer; Gavin E Reid
Journal:  J Am Soc Mass Spectrom       Date:  2011-07-06       Impact factor: 3.109

3.  Online nanoflow multidimensional fractionation for high efficiency phosphopeptide analysis.

Authors:  Scott B Ficarro; Yi Zhang; Marlene J Carrasco-Alfonso; Brijesh Garg; Guillaume Adelmant; James T Webber; C John Luckey; Jarrod A Marto
Journal:  Mol Cell Proteomics       Date:  2011-07-25       Impact factor: 5.911

Review 4.  NF-κB and STAT3 in glioblastoma: therapeutic targets coming of age.

Authors:  G Kenneth Gray; Braden C McFarland; Susan E Nozell; Etty N Benveniste
Journal:  Expert Rev Neurother       Date:  2014-09-29       Impact factor: 4.618

Review 5.  Development and maintenance of cancer stem cells under chronic inflammation.

Authors:  Toshihiko Tanno; William Matsui
Journal:  J Nippon Med Sch       Date:  2011       Impact factor: 0.920

Review 6.  Integrative biological analysis for neuropsychopharmacology.

Authors:  Mark R Emmett; Roger A Kroes; Joseph R Moskal; Charles A Conrad; Waldemar Priebe; Fernanda Laezza; Anke Meyer-Baese; Carol L Nilsson
Journal:  Neuropsychopharmacology       Date:  2013-06-26       Impact factor: 7.853

7.  Severe pulmonary arterial hypertension induced by SU5416 and ovalbumin immunization.

Authors:  Shiro Mizuno; Laszlo Farkas; Aysar Al Husseini; Daniela Farkas; Jose Gomez-Arroyo; Donatas Kraskauskas; Mark R Nicolls; Carlyne D Cool; Herman J Bogaard; Norbert F Voelkel
Journal:  Am J Respir Cell Mol Biol       Date:  2012-07-27       Impact factor: 6.914

8.  Discrimination of colon cancer stem cells using noncanonical amino acid.

Authors:  Xinrui Duan; Honglin Li; Hexin Chen; Qian Wang
Journal:  Chem Commun (Camb)       Date:  2012-07-30       Impact factor: 6.222

9.  Chromosome 19 annotations with disease speciation: a first report from the Global Research Consortium.

Authors:  Carol L Nilsson; Frode Berven; Frode Selheim; Huiling Liu; Joseph R Moskal; Roger A Kroes; Erik P Sulman; Charles A Conrad; Frederick F Lang; Per E Andrén; Anna Nilsson; Elisabet Carlsohn; Hans Lilja; Johan Malm; David Fenyö; Devipriya Subramaniyam; Xiangdong Wang; Maria Gonzales-Gonzales; Noelia Dasilva; Paula Diez; Manuel Fuentes; Ákos Végvári; Karin Sjödin; Charlotte Welinder; Thomas Laurell; Thomas E Fehniger; Henrik Lindberg; Melinda Rezeli; Goutham Edula; Sophia Hober; György Marko-Varga
Journal:  J Proteome Res       Date:  2012-12-18       Impact factor: 4.466

10.  Epigenetic regulation of CpG promoter methylation in invasive prostate cancer cells.

Authors:  Lesley A Mathews; Elaine M Hurt; Xiaohu Zhang; William L Farrar
Journal:  Mol Cancer       Date:  2010-10-07       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.